Pharma

Your Article Summary

See Latest Articles

Active Biotech Completes Patient Enrollment to TASQ Clinical Phase II study
Active Biotech, 06/09/09

Active Biotech announced that patient enrollment to the Phase II clinical trial for TASQ, a novel compound for the treatment of prostate cancer, is completed after enrollment of 200 patients into the study, according to the clinical protocol. The study is a 2:1 randomized, placebo-controlled, double-blind Phase II study of 1 mg/day TASQ versus placebo. The study encompasses symptom-free patients with metastatic, hormone-resistant, prostate cancer.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

Development of biomaterial scaffold for nerve tissue engineering: Biomaterial mediated neural regeneration
BMC: Journal of Biomedical Science, 11/30/09

ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition
ImmunoGen, Inc., 11/25/09

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09

 See all of Biotechnology

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease
Lundbeck, 11/30/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09

 See all of Drug Trials